CRISPR gene-editing technology has emerged as a promising tool to tackle genetic diseases. It was first used for therapy in 2020 to treat patients with sickle cell disease and beta-thalassemia, and now it is being used for conditions including cancer, AIDS, cystic fibrosis, muscular dystrophy, Huntington’s disease, blood disorders, and even COVID-19. However, due to potential risks and limitations, further research and careful monitoring are needed to enhance the safety and efficacy of CRISPR therapies.
Week in review: Axios npm supply chain compromise, critical FortiClient EMS bugs exploited
Here’s an overview of some of last week’s most interesting news, articles, interviews and videos: Financial groups lay out a plan to fight AI identity
